Longfei Fang

Longfei Fang joined Goodwin in 2022 as a department attorney in the firm’s Technology and Life Sciences groups.

Longfei represents biotechnology and pharmaceutical companies in connection with mergers and acquisitions, technology-based transactions, licensing and strategic partnerships as well as financing transactions.

Longfei’s experience includes representing:

Life Sciences Strategic Partnership & Licensing Transaction

• Medshine Discovery, Inc. in a license agreement with Erasca, Inc.
• Argo biopharma in two exclusive license and collaboration agreements with Novartis for cardiovascular assets
• Seagen in an exclusive worldwide license agreement for an ADC asset with Nona Biosciences
• Wuxi Biologics in a research service agreement with BioNTech SE to discover two targets of preclinical investigational monoclonal antibodies
• Biotheus Inc. in a collaboration, license and option agreement with BioNTech SE
• Biotheus Inc. in a strategic research collaboration, option and worldwide license agreement with BioNTech SE
• C4 Therapeutics in its Licensing Agreement with Betta Pharmaceuticals
• Duality Biologics in exclusive license and collaboration agreements for two ADC assets with BioNTech for upfront totaling $170 million, and milestone payments potentially totaling over $1.5 billion
• DualityBio Biologics in its exclusive option, license and collaboration agreement with BeiGene
• Inventisbio in its license and collaboration agreement with Chia-Tai Tianqing Pharmaceutical Group
• Luye Pharma Group in its license agreement with BeiGene
• Kelun-Biotech in its license and collaboration agreement with Merck & Co, Inc.
• Biosion USA, Inc. in its research and collaboration agreement with ImmunoGen, Inc.

M&A / VC Financing

• Proteologix in its acquisition by Johnson & Johnson for $850 million in cash and additional milestone payment
• SEED Therapeutics in its Series A-3 financing
• KBP Biosciences in its sale to Novo Nordisk of ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, for up to $1.3 billion
• LionRock Capital in its acquisition of Haglöfs AB from ASICS Corporation
• ZQ Capital in its acquisition of Popular Holdings Limited

Longfei is a qualified PRC patent agent. He is also a Certified Information Privacy Professional (CIPP/E).

Prior to joining Goodwin, Longfei was at another leading international law firm, where he focused on representing clients in cross-border patent litigation and intellectual property, M&A, and commercial transactions.

While attending law school, Longfei served as an Editor for the Columbia Science and Technology Law Review.